{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:07:49Z","timestamp":1768910869167,"version":"3.49.0"},"reference-count":65,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT"},{"name":"project \u201cHOPE\u2014Improving Ovarian Cancer Patients Survival\u201d"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Chemoresistance is a major obstacle in high-grade serous carcinoma (HGSC) treatment. Although many patients initially respond to chemotherapy, the majority of them relapse due to Carboplatin and Paclitaxel resistance. Drug repurposing has surfaced as a potentially effective strategy that works synergically with standard chemotherapy to bypass chemoresistance. In a prior study, using 2D cultures and two HGSC chemoresistant cell lines, it was demonstrated that combining Carboplatin or Paclitaxel with Pitavastatin or Ivermectin resulted in the most notable synergy. Acknowledging that 2D culture systems are limited in reflecting the tumor architecture, 3D cultures were generated to provide insights on treatment efficacy tests in more complex models. Objectives: We aimed to investigate whether combining Carboplatin or Paclitaxel with Pitavastatin or Ivermectin offers therapeutic benefits in a Cultrex-based 3D model. Methods: Here, the cytotoxicity of Carboplatin and Paclitaxel, both alone and in combination with Pitavastatin or Ivermectin, were analyzed on two chemoresistant tumor cell lines, OVCAR8 and OVCAR8 PTX R C, in 3D cultures. Cellular viability was assessed using CellTiter-Glo\u00ae Luminescent assays. Also, it explored synergistic interactions using zero interaction potency, Loewe, Bliss independence, and High-single agent reference models. Results: Our research indicates combining chemotherapeutic drugs with Pitavastatin or Ivermectin yields significantly more cytotoxic effects than chemotherapy alone. For all the combinations tested, at least one model indicated an additive effect; however, only the combination of Paclitaxel and Ivermectin consistently demonstrated an additive effect across all chemoresistant cell lines cultured in 3D models, as well as in all four synergy reference models used to assess drug interactions. Conclusions: Combining Paclitaxel with Ivermectin has the highest cytotoxic and the strongest additive effect for both chemoresistant cell lines compared to Paclitaxel alone.<\/jats:p>","DOI":"10.3390\/ph18010014","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T19:19:32Z","timestamp":1735154372000},"page":"14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4733-5778","authenticated-orcid":false,"given":"Mariana","family":"Nunes","sequence":"first","affiliation":[{"name":"Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, 4200-135 Porto, Portugal"},{"name":"Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-2226","authenticated-orcid":false,"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[{"name":"Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, 4200-135 Porto, Portugal"},{"name":"Associate Laboratory i4HB, Institute for Health and Bioeconomy, University Institute of Health Sciences (IUCS), University Polytechnic Higher Education Cooperative (CESPU), CRL, 4585-116 Gandra, Portugal"},{"name":"Applied Molecular Biosciences Unit (UCIBIO), Toxicologic Pathology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal"},{"name":"Oral Pathology and Rehabilitation Research Unit (UNIPRO), Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rickard, B.P., Conrad, C., Sorrin, A.J., Ruhi, M.K., Reader, J.C., Huang, S.A., Franco, W., Scarcelli, G., Polacheck, W.J., and Roque, D.M. (2021). Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 13.","DOI":"10.3390\/cancers13174318"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nunes, M., Henriques Abreu, M., Bartosch, C., and Ricardo, S. (2020). Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207768"},{"key":"ref_7","first-page":"651","article-title":"New drugs are not enoughdrug repositioning in oncology: An update","volume":"56","author":"Armando","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The Repurposing Drugs in Oncology (ReDO) Project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/ci500670q","article-title":"Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data","volume":"55","author":"Iwata","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ramos, A., Sadeghi, S., and Tabatabaeian, H. (2021). Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179451"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pharmthera.2006.08.002","article-title":"Interactions between drugs and occupied receptors","volume":"113","author":"Tallarida","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","article-title":"Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy","volume":"17","author":"Parhi","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/nl102184c","article-title":"Nanotechnology in drug delivery and tissue engineering: From discovery to applications","volume":"10","author":"Shi","year":"2010","journal-title":"Nano Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/1933719117750751","article-title":"Therapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence","volume":"25","author":"Zeybek","year":"2018","journal-title":"Reprod. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nunes, M., Duarte, D., Vale, N., and Ricardo, S. (2022). Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14184357"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nunes, M., Duarte, D., Vale, N., and Ricardo, S. (2022). The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010097"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, H., Hu, B., Shi, J., Chen, Y., and Huang, K. (2023). New insights into the therapeutic potentials of statins in cancer. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1188926"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-kappaB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105207","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jensen, C., and Teng, Y. (2020). Is It Time to Start Transitioning from 2D to 3D Cell Culture?. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00033"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Abuwatfa, W.H., Pitt, W.G., and Husseini, G.A. (2024). Scaffold-based 3D cell culture models in cancer research. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-00994-y"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Law, A.M.K., Rodriguez de la Fuente, L., Grundy, T.J., Fang, G., Valdes-Mora, F., and Gallego-Ortega, D. (2021). Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.782766"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jbiotec.2015.02.029","article-title":"Impact of the spheroid model complexity on drug response","volume":"205","author":"Hoffmann","year":"2015","journal-title":"J. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/labinvest.2013.41","article-title":"A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro","volume":"93","author":"Lee","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12967-020-02613-4","article-title":"Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): Targeted therapy","volume":"18","author":"Sheta","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_30","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"THE TOXICITY OF POISONS APPLIED JOINTLY","volume":"26","author":"BLISS","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_32","first-page":"93","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Duarte, D., Cardoso, A., and Vale, N. (2021). Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147408"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910450306","article-title":"Metallothionein gene expression and resistance to cisplatin in human ovarian cancer","volume":"45","author":"Schilder","year":"1990","journal-title":"Int. J. Cancer"},{"key":"ref_36","first-page":"7557","article-title":"Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1\/2","volume":"14","author":"Dang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_37","first-page":"635","article-title":"The employment of combinations of drugs in the chemotherapy of neoplasia: A review","volume":"17","author":"Goldin","year":"1957","journal-title":"Cancer Res."},{"key":"ref_38","first-page":"331","article-title":"The search for synergy: A critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Martirosyan, A., Clendening, J.W., Goard, C.A., and Penn, L.Z. (2010). Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-103"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2013.02.003","article-title":"Preclinical evaluation of statins as a treatment for ovarian cancer","volume":"129","author":"Robinson","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_41","first-page":"915","article-title":"Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro","volume":"8","author":"Jones","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"946","DOI":"10.18632\/oncotarget.5834","article-title":"The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer","volume":"7","author":"Stine","year":"2016","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E7301","DOI":"10.1073\/pnas.1705441114","article-title":"In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer","volume":"114","author":"Kodama","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt\/mTOR Signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Urzi, O., Gasparro, R., Costanzo, E., De Luca, A., Giavaresi, G., Fontana, S., and Alessandro, R. (2023). Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512046"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Manduca, N., Maccafeo, E., De Maria, R., Sistigu, A., and Musella, M. (2023). 3D cancer models: One step closer to in vitro human studies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1175503"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13619-020-00059-z","article-title":"Organoid based personalized medicine: From bench to bedside","volume":"9","author":"Li","year":"2020","journal-title":"Cell Regen."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.trecan.2020.10.009","article-title":"3D In Vitro Model (R)evolution: Unveiling Tumor-Stroma Interactions","volume":"7","author":"Rodrigues","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","article-title":"Towards precision oncology with patient-derived xenografts","volume":"19","author":"Zanella","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1186\/s12967-024-05824-1","article-title":"Advancing cancer research through organoid technology","volume":"22","author":"Zeng","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/2767-9764.CRC-23-0243","article-title":"Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models","volume":"3","author":"Mao","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/cts.12727","article-title":"Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer","volume":"13","author":"Bouhaddou","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., and Yu, L. (2020). The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00343"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nunes, M., Bartosch, C., Abreu, M.H., Richardson, A., Almeida, R., and Ricardo, S. (2024). Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options. Cells, 13.","DOI":"10.3390\/cells13090786"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nunes, M., Silva, P.M.A., Coelho, R., Pinto, C., Resende, A., Bousbaa, H., Almeida, G.M., and Ricardo, S. (2021). Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines with Increased Expression of P-Glycoprotein. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.752127"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpddr.2011.10.001","article-title":"P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance","volume":"2","author":"Lespine","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Seelig, A. (2020). P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.576559"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Veiga-Matos, J., Morales, A.I., Prieto, M., Remiao, F., and Silva, R. (2023). Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels. Molecules, 28.","DOI":"10.3390\/molecules28227532"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.20517\/cdr.2023.93","article-title":"Emerging roles of 3D-culture systems in tackling tumor drug resistance","volume":"6","author":"Nikdouz","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Filipiak-Duliban, A., Brodaczewska, K., Kajdasz, A., and Kieda, C. (2022). Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031166"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Langhans, S.A. (2018). Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00006"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.biocel.2011.12.009","article-title":"Intracellular trafficking of P-glycoprotein","volume":"44","author":"Fu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.drudis.2021.09.012","article-title":"Combining repurposed drugs to treat colorectal cancer","volume":"27","author":"Duarte","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: Visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat. Mach. Intell."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/14\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:00:00Z","timestamp":1760115600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ph18010014"],"URL":"https:\/\/doi.org\/10.3390\/ph18010014","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]}}}